DUBLIN–(BUSINESS WIRE)–The “Sinusitis – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Sinusitis – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Sinusitis (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Sinusitis (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Sinusitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 4, 4, 1, 10 and 1 respectively.
Sinusitis (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Sinusitis (Ear Nose Throat Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Sinusitis (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
- Introduction
- Sinusitis – Overview
- Sinusitis – Therapeutics Development
- Sinusitis – Therapeutics Assessment
- Sinusitis – Companies Involved in Therapeutics Development
- Sinusitis – Drug Profiles
- Sinusitis – Dormant Projects
- Sinusitis – Discontinued Products
- Sinusitis – Product Development Milestones
- Appendix
Companies Mentioned
- AnaptysBio Inc
- Argenx SE
- Armata Pharmaceuticals Inc
- Beijing Fogangren Bio-Pharm Tech Co Ltd
- Furen Pharmaceutical Group Co Ltd
- GeneOne Life Science Inc
- GlycoMira Therapeutics Inc
- Gossamer Bio Inc
- IVIEW Therapeutics Inc
- Kyowa Kirin Co Ltd
- Lyra Therapeutics
- Merck & Co Inc
- Nota Laboratories LLC
- OptiNose Inc
- Pfizer Inc
- Precigen Inc
- ProclaRx LLC
- Quorum Innovations LLC
- RAPT Therapeutics Inc
- Sanotize Research And Development Corp
- Wuhan Yicheng Biotechnology Co Ltd
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/77gtoa
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900